Table 3 Ongoing clinical trials to target TAMs in cancer patients

CSF1-R inhibitor

Pexidartinib (PLX3397)

Metastatic Breast Cancer + Eribulin

Ib/II

NCT01596751

Prostate Adenocarcinoma + Radiation Therapy + Antihormone Therapy

I

NCT02472275

Metastatic/Advanced Pancreatic or Colorectal Cancers + Durvalumab

I

NCT02777710

Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor

III

NCT02371369

DCC-3014

Sarcoma + Avelumab

I

NCT04242238

Advanced Tumors and Tenosynovial Giant Cell Tumor

I/II

NCT03069469

ARRY-382

Advanced Solid Tumors + Pembrolizumab

II

NCT02880371

Metastatic Cancer

I

NCT01316822

SNDX-6352

Unresectable Intrahepatic Cholangiocarcinoma + Durvalumab

II

NCT04301778

Solid Tumor + Durvalumab

I

NCT03238027

BLZ945

Advanced Solid Tumors + PDR001

I/II

NCT02829723

CSF1-R antibody

Cabiralizumab (BMS-986227)

Peripheral T Cell Lymphoma + Nivolumab

II

NCT03927105

Advanced Solid Tumors + Nivolumab

I

NCT02526017

Solid Tumors + Nivolumab + APX005M

I

NCT03502330

Pigmented Villonodular Synovitis/Diffuse Type Tenosynovial Giant Cell Tumor

I/II

NCT02471716

IMC-CS4 (LY3022855)

Solid Tumor

I

NCT01346358

Solid Tumor + Durvalumab/Tremelimumab

I

NCT02718911

Pancreatic Cancer + Cyclophosphamide + Pembrolizumab

I

NCT03153410

RO5509554/Emactuzumab/RG7155

Advanced Solid Tumors

I

NCT01494688

VEGFR/Aurora B/CSF1-R inhibitor

Chiauranib

Hepatocellular Carcinoma

I/II

NCT03245190

Small Cell Lung Cancer

I

NCT03216343

Ovarian Cancer

I/II

NCT03166891

VEGFR/KIT/RET/BRAF/CSF1-R inhibitor

Regorafenib

Hepatocellular Carcinoma + Nivolumab

I/II

NCT04170556

Hepatocellular Carcinoma

II

NCT04476329

VEGFR/FGFR/PDGFRβ/Kit/RET/TrkA/FLT3/CSF1-R inhibitor

Dovitinib (TKI258, Novartis)

Gastrointestinal Stromal Tumors

II

NCT01440959

MET/CSF1-R/SRC inhibitor

TPX-0022

Advanced Solid Tumors with MET mutation

I

NCT03993873

AXL/MER/CSF1-R inhibitor

Q702

Solid Tumor

I

NCT04648254

CCL2 antibody

CNTO888

Solid Tumors + Gemcitabine/Docetaxel/Paclitaxel and Carboplatin

I

NCT01204996

CCR2 antibody

MLN1202

Metastatic Cancer

II

NCT01015560

CCR2/5 inhibitor

BMS-813160

NSCLC/HCC + Nivolumab

II

NCT04123379

Pancreatic Ductal Adenocarcinoma + Gemcitabine + Nab-paclitaxel + Nivolumab

I/II

NCT03496662

CXCR4 inhibitor

BL-8040

Metastatic Pancreatic Adenocarcinoma + Pembrolizumab

II

NCT02907099

Plerixafor (Mozobil)

Advanced Pancreatic, Ovarian and Colorectal Adenocarcinomas

I

NCT02179970

Metastatic Pancreatic Cancer + Cemiplimab

II

NCT04177810

Bisphosphonates

Zoledronic Acid

Hormone-Refractory Prostate Cancer

II

NCT00636740

Bone Metastatic NSCLC

II

NCT04325776

Ibandronic Acid

Breast Cancer

II

NCT02616744

Alendronate Sodium

Breast Cancer

III

NCT00122356

Trabectedin

Trabectedin

Liposarcoma/Leiomyosarcoma

II

NCT02247544

Soft Tissue Sarcoma + Olaratumab

I

NCT03985722

Ovarian and Uterine Carcinosarcoma

II

NCT02993705

Malignant Pleural Mesothelioma

II

NCT02194231

Metastatic Adult Soft Tissue Sarcoma + Nivolumab

II

NCT03590210

Pancreatic Cancer

II

NCT01339754

Advanced Soft Tissue Sarcomas

II

NCT00003939

TLR 4 agonist

GLA-SE

Adult Soft Tissue Sarcoma

I

NCT02180698

Merkel Cell Carcinoma

I

NCT02035657

GSK1795091

Cancer

I

NCT02798978

TLR 7/8 agonist

TransCon TLR7/8 Agonist

Solid Tumor + Pembrolizumab

I/II

NCT04799054

BDB018

Solid Tumor + Pembrolizumab

I

NCT04840394

NKTR-262

Solid Tumor

I/II

NCT03435640

TLR 7 agonist

RO7119929

Hepatocellular Carcinoma, Biliary Tract Cancer, Solid Tumors With Hepatic Metastases

I

NCT04338685

Imiquimod

Breast Cancer

II

NCT00899574

TLR 9 agonist

SD-101

Pancreatic Adenocarcinoma + Nivolumab + Radiation Therapy

I

NCT04050085

Solid Tumor + BMS 986,178

I

NCT03831295

CMP-001

Melanoma + Pembrolizumab

II

NCT04708418

Pancreatic Adenocarcinoma and Melanoma + INCAGN01949

I/II

NCT04387071

IMO-2125 (Tilsotolimod)

Refractory Melanoma + Ipilimumab

III

NCT03445533

Malignant Melanoma

II

NCT04126876

EMD 1,201,081

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck + Cetuximab

II

NCT01040832

CD40 agonist antibody

Selicrelumab (RO7009789)

Solid Tumors + Atezolizumab

I

NCT02304393

RO7300490

Solid Tumors + Atezolizumab

I

NCT04857138

LVGN7409

Cancer

I

NCT04635995

CP-870,893

Melanoma + Tremelimumab

I

NCT01103635

Mitazalimab

Metastatic Pancreatic Ductal Adenocarcinoma + Chemotherapy

I/II

NCT04888312

CDX-1140

Breast Cancer + CDX-301, Radiotherapy, and Poly-ICLC

I

NCT04616248

APX005M

Neoadjuvant Therapy for Rectal Cancer + Chemotherapy

II

NCT04130854

Anti-CD47 antibody

ZL-1201

Advanced Cancer

I

NCT04257617

IBI188

Advanced Malignancies

I

NCT03717103

Hu5F9-G4

Solid Tumor

I

NCT02216409

STI-6643

Solid Tumor

I

NCT04900519

AK117

Neoplasms Malignant

I

NCT04728334

ALX148

Head and Neck Cancer + Pembrolizumab

II

NCT04675294

AO-176

Solid Tumor

I/II

NCT03834948

Anti-CD47/PD-1 bispecific antibody

HX009

Advanced Solid Tumor

II

NCT04886271

Advanced Solid Tumor

I

NCT04097769

PF-07257876

Advanced or Metastatic Tumors

I

NCT04881045

IBI322

Advanced Solid Tumor

I

NCT04912466

Advanced Solid Tumor

I

NCT04338659

Advanced Solid Tumor

I

NCT04328831

PI3Kγ inhibitor

IPI-549

Head and Neck Squamous Cell Carcinoma

II

NCT03795610

Modified Vitamin D Binding Protein Macrophage Activator

EF-022

Solid Tumors

I

NCT02052492

Migration Inhibitory Factor (MIF)

Anti-MIF Antibody

Malignant Solid Tumors

I

NCT01765790